ORPHAN DRUG POLICY by GOEL, ROSHANI
Vol 9, Issue 1, 2021 ISSN - 2321-550X
ORPHAN DRUG POLICY
ROSHANI GOEL*
Sanrachna, SGT University, Gurugram, Haryana, India. Email: roshani_sanrachna@sgtuniversity.org
Received: 21 December 2020, Revised and Accepted: 03 January 2021
ABSTRACT
Pharmaceutical industry is crucial for mankind and contributes in some way in socio economic development of the society through jobs, community 
welfare, and supply chains. Indian pharmaceutical companies are one of the largest markets in the world, estimated 10% of global production and 2% 
of world market. The industry is has shown significant growth in infrastructure development, producing wide range of pharmaceutical products with 
new technical advancements. The country is famous for producing and providing pharmaceutical products at much cheaper prices than the US and 
EU. However, the country lacks in investment in research on rare disease or orphan drugs. This paper tries to highlight the ways in which the market 
in orphan drugs can grow in India with the help of international partners.
Objective: The objective of the study was to look at existing orphan drug policies and how we can aim at making it more equitable in India. 
Methods: Research is completely based on secondary data from online journals and government data. The study is analytical in its approach and is 
descriptive in nature. 
Results: Pharmaceutical companies invest less in Orphan drugs as they do not mark an assured profit with present investment.
Conclusions: To maintain the interest of Indian pharmaceutical companies it is suggested that, Indian companies should work in collaboration with 
countries which lead in orphan drug markets. 
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INTRODUCTION
Millions of people in developing countries do not have access to health-
care services and medications which are available in developed countries. 
Most of the rare diseases are genetic in nature. They disproportionately 
impact children: 50% of new cases are in children and are responsible 
for 35% of deaths before the age of 1 year, 10% between the age of 1 
and 5 years, and 12% between 5 and 15 years [1]. However, the most 
neglected diseases by pharma industries are tropical diseases that are 
caused by parasites and spread by insects or contaminated water or soil, 
for example [2]. Development of orphan drug policies is least concern of 
pharmaceutical companies. They work on the calculation of number of 
vaccines manufactured on cost of per vaccination. Market is a precious 
venture for pharmaceutical companies. They are hesitant on the sale of the 
product. Development of such drugs relies heavily on intellectual property 
rights to ensure the return of money invested on it. However, in India, 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) has been 
introduced but has not been enforced as big companies provide medicines 
at cheap prices [3]. Therefore, the paper tries looking at policies that can 
make pharma companies to invest more on the research of orphan drugs. 
DISCUSSION
Rare diseases are chronic and life-threatening illness that requires 
proper long-term medical treatment. As these diseases are rare, so 
the development of medication requires considerable amount of fund 
which affect the family of a patient suffering from rare disease. Thus, 
Government of India asked Ministry of Health and Family Welfare 
to draft a policy on treatment of rare disease because of the above-
mentioned reasons. Hence, the Ministries looked at multisectoral 
approach to prepare India to tackle the problem of rare disease in areas 
like estimating the number that can affect or had affected the person, 
research on medication and diagnostic of disease, awareness, training 
of health caregivers, and affordability of treatment. Government 
of India recommends policies which mark a balance between the 
affordability of treatment and sustaining of medical research centers. 
This paper also marks a shift from health economics to managerial 
perspective by looking at societal values of orphan drugs in a realm of 
sustainable development from two categories: (1) Social equality and 
(2) inclusiveness perspective through the example of COVID-19.
If we apply international estimation of 6–8% people getting affected by 
rare disease, then in India, it has affected 72–96 million people which 
is a significant number [1]. The economic burden in such scenarios for 
rare diseases left unknown which puts a challenge in estimating the 
funds required for research. 
However, Hughes professor at Bangor University stated in his study that 
companies with orphan drug authorization have more investment and 
profitable opportunities that non orphan drugs; as incentives related to 
research reduce marketing cost and premium pricing. In support to the 
argument, orphan drug market grows at a compound annual growth 
rate [4]. The market is expected to reach $178 billion by 2020 and 
Defrag account for 19% of total branded prescription drug sales [5]. 
The major pharmaceutical sales originate from the US, EU, and Japan. 
Together, they account for 80% of global market. The U.S itself accounts 
for 45% of pharmaceutical sales, then Europe 24% and Japan 11%. 
Further, the cost of treatment and medication is much expensive in the 
U.S; and orphan drug cost per patient in the U.S is 4.5 times higher than 
non-orphan drug cost. In recent times, the median between the price of 
orphan and non- orphan is reduced by 50% in the U.S. This shows market 
exclusivity. Companies working on coronavirus treatment are registered 
as rare disease treatment with the US regulatory, a status which is worth 
million in tax breaks. Celgene, Abbvie, and Johnsons & Johnsons are the 
leading companies of orphan drug market [6]. Gilead Sciences comes 
on 13th position accounting for $0.4 billion worldwide orphan drug sale 
in 2018 with 0.7% market share. They have been successful in making 
an experimental drug remdesivir for treating coronavirus and have 
also taken permission from Food and Drug Administration to use it on 
patients suffering from COVID-19. In addition, more than 50 drugs have 
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been made to cure coronavirus patients worldwide. The emergency for 
inventing a vaccine for COVID-19 is because it has spread across borders, 
including countries with poor health system. 
In India to stimulate research regarding rare diseases and development 
of its medication, authorities and ministries have incentivized 
biotechnology and health industries. To accelerate the research for 
orphan drugs countries like India have provided incentivization to 
pharmaceutical companies that is, including tax benefits and have 
increased the period of market exclusivity to maintain the interest 
of the companies. About 70% of domestic demand for bulk drugs is 
delivered by the Indian pharmaceutical industries. With 40% of total 
pharmaceutical products are exported, out of which 55% of total export 
constitute formulation and 45% consists of bulk drugs. “The Indian 
Pharmaceutical Industry is one of fastest emerging international center 
for contract research and manufacturing services or CRAMS.” The 
reason for its emergence is international high quality with low cost. 
India has biggest number of the US Food and Drug Administration. The 
manufacturing cost of drugs is half of the price than in the U.S., and the 
cost incurring for research is 8 times more in the U.S. This indicates 
India’s service deliverance globally at lower cost [7]. 
It is crucial for Indian pharmaceutical companies to work in 
collaboration with the U.S registered rare treatment pharma 
companies as their market investment will help Indian pharma 
companies to conduct research and develop vaccines at lower price. 
However, policy is always made with an understanding that people will 
look for good health care and services. Pricing of medicines is crucial 
for consideration while developing a policy. Lower cost will directly 
affect the cost of the treatment. Furthermore, product patent has been 
introduced in the country. Furthermore, a “Pharmaceutical Research 
and Development Support Fund with a corpus of Rs.150 crores has 
been set up under the administrative control of the Department of 
Science and Technology” [8]. To encourage pharma companies to work 
on orphan drugs, it is important to increase time for renewal of orphan 
drug, for example, person who is eligible for grants, for example, in 
Japan orphan drug applicant receives consultation from Ministry of 
Health, Labour, and Welfare for free, increase in time period of product 
renewal for orphan drug, and government support doctors to use the 
product [4]. 
Government has always allowed smooth functioning of pharma 
companies. These pharma companies have enjoyed trade surplus 
since 1987, because of which it was expected that Indian pharma 
companies will increase the manufacturing of generic drugs 
worldwide. Their effort to increase export some of the pharma 
companies has established their marketing and trade supporting 
centers in developed countries and launched generic segments 
as cheaper alternatives to branded products. At national level, 
as policy-making ought to involve level of ministries, it is highly 
recommended to look on the smooth implementation mechanism. 
For example, corpus funds should not only be made available by 
center and the state government but also by local authorities for easy 
access by local health centers [9]. Furthermore, government needs 
to set up its own diagnostic laboratories and research departments 
to create epidemiological data. Better infrastructure leads to a 
development of the department. More focus needs to have on 
biogenetics as they account for 50% of orphan drug market globally. 
Furthermore, revision on drugs and their usage need to be done1. 
All these recommendations can help in striking a balance between 
pharmaceutical companies to work for orphan drug. 
CONCLUSION
The scenario of orphan drugs stands differently in developing countries 
like India than in developed countries. The issue is approached 
differently as nature of this practice is linked with high costs with 
fewer returns. Government approach to it through incentivization 
has led a paradigm shift in pharmaceutical companies toward orphan 
drugs. Nevertheless, the lack of interest of Indian medical institutions 
toward orphan drugs has led poor awareness among public. To tackle 
the problem of interest of pharmaceutical companies in investing in 
orphan drugs, government established legislation as well as provided 
corpus fund to reduce premium pricing of drugs. This will make the 
vaccine available for people who cannot afford it. However, working 
with companies worldwide will help in the development of medicines 
at lower cost. 
1. Products withdrawn from the market for economic or therapeutic reasons. Few drugs which are 
withdrawn from the market for some reasons, e.g., thalidomide widely used as a hypnotic 
drug some years ago for its high teratogenic (triggering fetal malformations) risk may show 
a very interesting therapeutic application, i.e., analgesic proprieties in rare diseases such as 
leprosy and lupus erythematosus. These are diseases for which no satisfactory treatment is 
available (Sharma, Jacob, Tandon, and Kumar, 2010).
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